Tracking tiny patients: major study launches to monitor blood thinner safety in infants

NCT ID NCT05900388

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study aims to collect real-world information on how doctors prescribe and use blood-thinning medications (like rivaroxaban) to treat dangerous blood clots in babies and toddlers under 2 years old. Researchers will review the medical records of about 850 children who are already receiving this standard care to understand treatment patterns and monitor for serious bleeding events. The goal is to gather safety and usage data to better inform future care for this very young, vulnerable patient group.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many locations

    Multiple Locations, Denmark

  • Many locations

    Multiple Locations, France

  • Many locations

    Multiple Locations, Spain

  • Many locations

    Multiple Locations, Sweden

Conditions

Explore the condition pages connected to this study.